LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
3.25
3.25
Year Range
1.81
5.06
Daily Change
-1.81%
Monthly Change
+1.25%
6 month change
+58.54%
Year Change
+16.49%
Previous Close
3.3 1
Open
3.2 5
Low
3.2 5
High
3.2 5
Volume
4
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
Income statement Balance sheet Cash flow
Value 20202021202220232024 TTM

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

News